Immunotherapy By Cancer Type

Let's spread the word about Immunotherapy! Click to share this page with your community.
Immunotherapy: Impacting All Cancers

Immunotherapy is a form of cancer treatment that uses the power of the body's immune system to prevent, control, and eliminate cancer. From the preventive vaccine for cervical and liver cancer to the first therapy ever proven to extend the lives of patients with metastatic melanoma, immunology has already led to major treatment breakthroughs for a number of cancers. Every cancer type is unique, though, and immunology and immunotherapy are impacting each cancer in different ways.

Explore immunotherapies by cancer type and explore different kinds of treatment, why immunotherapy matters, and how to support cancer immunotherapy research.

Bladder Cancer
The first FDA-approved immunotherapy treatment—Bacillus Calmette-Guérin cancer vaccine—was for bladder cancer in 1990.
Brain Cancer
Cancers of the brain and nervous system are relatively rare but very serious. Immunotherapy is showing significant promise where other approaches have failed.
Breast Cancer
New studies of immunotherapy in the treatment of breast cancer, one of the most commonly diagnosed cancer types among women globally, are encouraging, with the potential for long-term success.
Cervical Cancer
Three preventive cancer vaccines are already helping to stop cervical cancer, and many new immunotherapeutic approaches are in clinical trials.
Childhood Cancer
Immunotherapy offers a potential way to treat childhood (pediatric) cancer without the damaging, long-term side effects of conventional treatments.
Colorectal Cancer
There are several FDA-approved immunotherapies for colorectal cancer, for which patients are in urgent need of new treatment options.
Esophageal Cancer
Better treatments for esophageal cancer are urgently needed and immunotherapy research holds the promise of new therapeutic options.
Head and Neck Cancer
Immunotherapy offers new treatment options for patients with cancers of the mouth, throat, voice box, sinuses, nose, and salivary glands.
Kidney Cancer
Beyond cytokines and targeted therapies, several new immunotherapies are becoming important in the treatment of kidney (renal) cancer.
There are several FDA-approved immunotherapy treatments for leukemia (leukaemia) and ongoing research demonstrates even greater potential for new treatments.
Liver Cancer
In addition to the first FDA-approved hepatitis B preventive cancer vaccine, immunotherapy treatments can enhance the immune system’s response to liver cancer.
Lung Cancer
Immunotherapy is a promising treatment option for advanced lung cancer, alone or in combination with conventional treatments like chemotherapy or surgery.
Several FDA-approved immunotherapies offer treatment options to children and adults with Hodgkin and non-Hodgkin lymphoma.
The future of melanoma treatment is evolving, thanks to the revolutionary advancements in immunotherapy for skin cancers.
Multiple Myeloma
Immunotherapy is a promising new treatment option for multiple myeloma patients, with the potential for long-term cancer remission after bone marrow transplantation.
Ovarian Cancer
Research into immunotherapy for ovarian cancer is promising, especially since more treatment options for patients and oncologists are urgently needed.
Pancreatic Cancer
Pancreatic cancer has few treatment options, so pancreatic cancer immunotherapy research is vital to providing patients with new hope.
Prostate Cancer
With a cancer vaccine and checkpoint inhibitor already approved, immunotherapy research offers new hope to patients with advanced prostate cancer.
Immunotherapy research is vital for providing new treatment options for patients, both adults and children, with sarcoma.
Skin Cancer
Skin cancers are common, often diagnosed at an early stage, and among the first cancers to respond to immunotherapy.
Stomach Cancer
Immunotherapies, including checkpoint inhibitors and targeted antibodies, offer promising new treatment options for stomach (gastric) cancer patients.

*Immunotherapy results may vary from patient to patient.